Supplementary Information Files for 'Distributed automated manufacturing of pluripotent stem cell products'Abstract:Establishing how to effectively manufacture cell therapies is an industry-level problem. Decentralised manufacturing is of increasing importance, and its challenges are recognised by healthcare regulators with deviations and comparability issues receiving specific attention from them. This paper is the first to report the deviations and other risks encountered when implementing the expansion of human pluripotent stem cells (hPSCs) in an automated three international site–decentralised manufacturing setting. An experimental demonstrator project expanded a human embryonal carcinoma cell line (2102Ep) at three development sites i...
A major reason for the current reproducibility crisis in the life sciences is the poor implement...
Human stem cells have the potential to transform medicine. However, hurdles remain to ensure that ma...
Human embryonic stem cells (hESCs) have the potential to provide a limitless supply of somatic cells...
Establishing how to effectively manufacture cell therapies is an industry-level problem. Decentralis...
Human embryonic stem cells (hESCs) hold great promise for cell-based therapies and drug screening ap...
Quality approaches to allow multi-site equivalence in pluripotent stem cell based product manufactur...
The translation of experimental cell-based therapies to volume produced commercially successful clin...
Consistent and robust manufacturing is essential for the translation of cell therapies, and the util...
Autologous cell therapies are currently being evaluated in multiple clinical trials and are becoming...
For almost two decades it is claimed that cell-based therapies will revolutionize the field of medic...
Tissue engineering and regenerative medicine are rapidly developing fields that use cells or cell ba...
AbstractThe transfer of a laboratory process into a manufacturing facility is one of the most critic...
Enabling stem cell-base therapies requires innovative solutions to close the gaps which exist betwee...
A major reason for the current reproducibility crisis in the life sciences is the poor implementatio...
Introduction: Current production facilities for Cell-Based Health care Products (CBHPs), also referr...
A major reason for the current reproducibility crisis in the life sciences is the poor implement...
Human stem cells have the potential to transform medicine. However, hurdles remain to ensure that ma...
Human embryonic stem cells (hESCs) have the potential to provide a limitless supply of somatic cells...
Establishing how to effectively manufacture cell therapies is an industry-level problem. Decentralis...
Human embryonic stem cells (hESCs) hold great promise for cell-based therapies and drug screening ap...
Quality approaches to allow multi-site equivalence in pluripotent stem cell based product manufactur...
The translation of experimental cell-based therapies to volume produced commercially successful clin...
Consistent and robust manufacturing is essential for the translation of cell therapies, and the util...
Autologous cell therapies are currently being evaluated in multiple clinical trials and are becoming...
For almost two decades it is claimed that cell-based therapies will revolutionize the field of medic...
Tissue engineering and regenerative medicine are rapidly developing fields that use cells or cell ba...
AbstractThe transfer of a laboratory process into a manufacturing facility is one of the most critic...
Enabling stem cell-base therapies requires innovative solutions to close the gaps which exist betwee...
A major reason for the current reproducibility crisis in the life sciences is the poor implementatio...
Introduction: Current production facilities for Cell-Based Health care Products (CBHPs), also referr...
A major reason for the current reproducibility crisis in the life sciences is the poor implement...
Human stem cells have the potential to transform medicine. However, hurdles remain to ensure that ma...
Human embryonic stem cells (hESCs) have the potential to provide a limitless supply of somatic cells...